269 related articles for article (PubMed ID: 9495454)
21. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
22. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
23. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
25. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Hatanaka H; Abe Y; Naruke M; Asai S; Miyachi H; Kawakami T; Nagata J; Kamochi J; Kijima H; Yamazaki H; Scanlon KJ; Ueyama Y; Nakamura M
Anticancer Res; 2001; 21(2A):879-85. PubMed ID: 11396179
[TBL] [Abstract][Full Text] [Related]
26. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
27. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
28. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
29. Cellular uptake and interaction with purified membranes of rebeccamycin derivatives.
Goossens JF; Hénichart JP; Anizon F; Prudhomme M; Dugave C; Riou J; Bailly C
Eur J Pharmacol; 2000 Feb; 389(2-3):141-6. PubMed ID: 10688977
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.
Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J
Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623
[TBL] [Abstract][Full Text] [Related]
31. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
[TBL] [Abstract][Full Text] [Related]
32. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.
Vanhoefer U; Müller MR; Hilger RA; Lindtner B; Klaassen U; Schleucher N; Rustum YM; Seeber S; Harstrick A
Br J Cancer; 1999 Dec; 81(8):1304-10. PubMed ID: 10604726
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
34. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
35. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
37. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
[TBL] [Abstract][Full Text] [Related]
38. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
39. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.
Gaj CL; Anyanwutaku I; Chang YH; Cheng YC
Biochem Pharmacol; 1998 Apr; 55(8):1199-211. PubMed ID: 9719474
[TBL] [Abstract][Full Text] [Related]
40. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
